TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33789592
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg
Study: 32033922
Drug: LSD (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (13 μg)
Study: 37323099
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneously every 6 months)
Study: 34109545
Drug: Coached clinics
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coached clinics (received online toolkit plus weekly assistance from a distance coach for 12 months)
Study: 33020648
Drug: Spartalizumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab (400 mg every 4 weeks) + Dabrafenib (150 mg twice daily) + Trametinib (2 mg once daily)
Study: 34350657
Drug: Short wavelength
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short wavelength bright light therapy (BLT)
Study: 34350657
Drug: Long wavelength
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long wavelength bright light therapy (BLT)
Study: 35030011
Drug: Spartalizumab 400
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily
Study: 35030011
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily
Study: 32696895
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) with antidepressants
Study: 33120777
Drug: Antidepressants only
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants only (Control)
Study: 33952735
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of vegetable oil of Vitis vinifera L. or Persea americana L. (10 mL)
Study: 34764637
Drug: Remimazolam (a
Normalized name: remimazolam (as besylate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (a bolus of 0.1 mg kg‐1, iv)
Study: 34764637
Drug: Lidocaine (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (a bolus of 0.5 mg kg‐1, iv)
Study: 32584935
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of UDCA
Study: 32584935
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of UDCA
Study: 37806651
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily
Study: 33912695
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy
Study: 32632956
Drug: PUVA maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA maintenance treatment
Study: 35258839
Drug: TA-ER 32
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-ER 32 mg
Study: 35258839
Drug: TAcs 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAcs 40 mg
Study: 35034431
Drug: Gadolinium injection
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium injection at 1 times dose (Group A)
Study: 35034431
Drug: Gadolinium injection
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium injection at 1.5 times dose (Group B)
Study: 35034431
Drug: Gadolinium injection
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium injection at 2 times dose (Group C)
Study: 33757719
Drug: Sham cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham cupping therapy
Study: 35115337
Drug: UC+TCZ (tocilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC+TCZ (tocilizumab 8 mg·kg‐1)
Study: 35115337
Drug: UC+SARI (sarilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC+SARI (sarilumab 200 mg)
Study: 33472211
Drug: Oxytocin challenge
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin challenge test (OCT) - infusion of oxytocin 5 IU/500 mL Ringer lactate at a rate of 12 mL/h, doubling every 10 min until inducing 5 uterine contractions per 15-min interval.
Study: 37830344
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin
Study: 34837528
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy (5 days a week for 3 weeks at 45 °C for 30 min each day)
Study: 34837528
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy
Study: 34837528
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping (6 treatment days 2 times a week)
Study: 32663119
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy in 5 once-weekly fractions of 6.0 Gy
Study: 32663119
Drug: 28.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28.5 Gy in 5 once-weekly fractions of 5.7 Gy
Study: 32653055
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% twice daily
Study: 32653055
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% once daily
Study: 32653055
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 0.5% once daily
Study: 32653055
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 0.15% once daily
Study: 32653055
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream (all doses)
Study: 36107535
Drug: Liriope platyphylla
Normalized name: Liriope spicata tuber extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liriope platyphylla extract (LP) 1000 mg per day for 4 weeks
Study: 36107535
Drug: Placebo (dextrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrin) 1000 mg per day for 4 weeks
Study: 34585252
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intrathecal methotrexate
Study: 34585252
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intrathecal methotrexate
Study: 39363320
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy
Study: 33449392
Drug: Lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 80 mg/day
Study: 35802191
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate air‐powder abrasion supplemented by amino acid buffered hypochlorite solution (test-group 2)
Study: 32967877
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²) followed by intravenous immunoglobulin (IVIg) with an initial dose of 2 g/kg and 1.5 g/kg injections once a month for 5 months (maximum dose: 100 g)
Study: 32967877
Drug: Rituximab alone
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab alone (375 mg/m²)
Study: 34044830
Drug: Butorphanol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2.5 μg/kg
Study: 34044830
Drug: Butorphanol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 5 μg/kg
Study: 34044830
Drug: Butorphanol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 7.5 μg/kg
Study: 34044830
Drug: Butorphanol 10
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 10 μg/kg
Study: 33750085
Drug: Telerehabilitation (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (8 weeks, 5 days/week, daily cost of 74 PLN)
Study: 35209847
Drug: Fentanyl 8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 8.3 μg/kg
Study: 35209847
Drug: Oxycodone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.5 mg/kg
Study: 35209847
Drug: Butorphanol 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.16 mg/kg
Study: 34446504
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg spironolactone daily, increasing to 100 mg until week 24
Study: 32454209
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg psilocybin
Study: 36342289
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) 12 ml twice daily
Study: 33507722
Drug: Daily GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GnRH agonist for luteal phase support (0.2 mg subcutaneous injection bid) following GnRH agonist trigger
Study: 33507722
Drug: Standard strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS)
Study: 32966811
Drug: Surufatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib (300 mg per day)
Study: 34450042
Drug: Hypothermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia treatment for moderate or severe neonatal encephalopathy
Study: 34619073
Drug: Treatment rationale
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment rationale for iCBT
Study: 34619073
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment rationale for iCBT
Study: 32253184
Drug: Bimekizumab 64
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab 64 mg
Study: 32253184
Drug: Bimekizumab 160
Normalized name: Bimekizumab 160 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 160 mg
Study: 32253184
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg
Study: 35619097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of feedback modifications
Study: 34129601
Drug: Pyronaridine-artesunate, fixed-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine-artesunate, fixed-dose, once daily for 3 days, dosed by body weight, using tablet formulation for adults/adolescents and pediatric granule formulation for children/infants under 20 kg.
Study: 34610286
Drug: 20% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% hypertonic dextrose injection
Study: 36237908
Drug: Zilver PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilver PTX drug-eluting stent (DES)
Study: 36104179
Drug: LIPUS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPUS therapy (1.3 MPa, 32 cycles, 5% duty cycle, 1 hour, 3 times a week for 6 sessions over 1.5 years)
Study: 36104179
Drug: LIPUS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPUS therapy
Study: 35124675
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care primary healthcare treatment
Study: 32590064
Drug: Thigh-high compression
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh-high compression stockings (CS) and sequential compression devices (SCDs)
Study: 32590064
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices (SCDs) alone
Study: 36307040
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg every 2 weeks)
Study: 32294530
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab (durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w × 4, then durvalumab 10 mg/kg q2w)
Study: 33704831
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical treatment alone)
Study: 33030225
Drug: Low-Dose, Open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose, Open Food Challenge
Study: 36364716
Drug: Food guiding
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food guiding booklet (G)
Study: 36364716
Drug: Monthly income
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly income of 3000−5000
Study: 33992562
Drug: Baroreflex Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex Activation Therapy (BAT) plus guideline-directed medical therapy (GDMT)
Study: 35143442
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) therapy combined with 4% hydroquinone (HQ) cream
Study: 35143442
Drug: 4% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone (HQ) cream alone
Study: 33586842
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and adjuvant radiation therapy
Study: 32103439
Drug: Intraventricularly delivered,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricularly delivered, sustained-release nimodipine (EG-1962)
Study: 32103439
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care oral nimodipine (NEWTON 2)
Study: 32680475
Drug: Behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural group counselling program for smoking cessation, optional nicotine replacement therapy, environmental smoking reduction measures
Study: 33513064
Drug: Remote Hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote Hypnotic Induction Profile (rHIP)
Study: 32681659
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment
Study: 36296930
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy (CBT)
Study: 33442915
Drug: VR intervention
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR intervention (8 h within 2 weeks) plus 8-h occupational therapy (OT)
Study: 34137527
Drug: Articaine 4%
Normalized name: ARTICAINE 4%/EPI 1:200000 INJ CART 1.7ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 4% IANB with Buccal Infiltration
Study: 34137527
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% IANB with Buccal Infiltration
Study: 34155568
Drug: Brivaracetam 50
Normalized name: brivaracetam 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 50 mg/day
Study: 32728734
Drug: HERO intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HERO intervention (8-session cognitive-behavioral therapy)
Study: 34501459
Drug: Electrochemotherapy (ECT)
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemotherapy (ECT) followed by conventional systemic treatment (FOLFOXIRI)
Study: 34501459
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (FOLFOXIRI)
Study: 615704919
Drug: C1INH (20U/kg/dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1INH (20U/kg/dose) intra-operatively, then 2x weekly for 7 doses
Study: 34398236
Drug: Romidepsin (RMD)
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin (RMD) 5 mg/m2 in multidose cohort 4
Study: 32459776
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum injections
Study: 36858265
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment for 8 weeks
Study: 32317748
Drug: 320 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg/day anthocyanin
Study: 32317748
Drug: Anthocyanin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin supplementation (0-320 mg/day)
Study: 32317748
Drug: Anthocyanin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin supplementation (80-320 mg/day)
Study: 32413002
Drug: Contrast-rebalanced binocular
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-rebalanced binocular game treatment (1 hour a day, 5 days a week)
Study: 32413002
Drug: Patching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching treatment (2 hours a day, 7 days a week)
Study: 35600486
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy
Study: 32832978
Drug: Fremanezumab (quarterly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fremanezumab (quarterly or monthly dosing)
Study: 33893671
Drug: Zinc (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (30 mg)
Study: 34591428
Drug: Regional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional radiation therapy 50‐55 Gy and intermediate dose of α2b‐interferon (RT + IFN)
Study: 34591428
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose of α2b‐interferon alone (IFN)
Study: 34331551
Drug: Indobufen 100
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 100 mg twice daily
Study: 33481052
Drug: SPP-24 levels
Normalized name: CAPSICUM SPP.
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP-24 levels measured in serum using ELISA; mean SPP-24 was 167.7 ± 101.1 ng/mL (range 33.4–633.6 ng/mL)
Study: 32613644
Drug: Online Acceptance
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Acceptance and Commitment Therapy (ACT)
Study: 34269493
Drug: Online Compassion-Focused
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online Compassion-Focused Therapy (CFT)
Study: 34728250
Drug: TAU augmented
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU augmented with the 5-min FoodT app daily for 4 weeks (n = 40)
Study: 34728250
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n = 40)
Study: 33491367
Drug: Conical Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical Standard (CS) implants
Study: 33491367
Drug: Internal Hex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal Hex (IH) implants
Study: 33491367
Drug: CS implants
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS implants
Study: 33491367
Drug: CS and
Normalized name: HYPNOTICS AND SEDATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS and IH implants
Study: 34515098
Drug: Thulium laser
Normalized name: thulium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thulium laser (L)
Study: 34515098
Drug: Combined L-PDT
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined L-PDT
Study: 32796401
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii CNCM I‐3799 (5 billion CFU twice daily for 5 days)
Study: 32956178
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) monotherapy
Study: 35533340
Drug: Burosumab (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab (0.8 mg/kg every 2 weeks)
Study: 34658725
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of propofol
Study: 32851876
Drug: BUP-NX (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-NX (sublingual buprenorphine-naloxone)
Study: 32851876
Drug: XR-NTX (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (extended-release injection naltrexone)
Study: 34619894
Drug: Immediate rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate rehabilitation by using implant-supported full-arch prostheses (TG)
Study: 34619894
Drug: Immediate rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate rehabilitation of implant-supported full-arch prostheses (CG)
Study: 35149373
Drug: Music medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music medicine
Study: 33042579
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as no treatment)
Study: 34113318
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment
Study: 34146512
Drug: Pioglitazone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (0.8 mg/day sustained release)
Study: 35671649
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LD-MTX)
Study: 34606758
Drug: Tablet administration
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administration of FAMCAT
Study: 34606758
Drug: Interview administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview administration of FAMCAT
Study: 34988564
Drug: Riceberry rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riceberry rice beverage (RRB) with HCMF meal (2 g of riceberry rice extract powder/400 ml)